You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

My medicine

This page is specifically for patients who have been prescribed Trelegy Ellipta. If you are not a patient, please return to the public website.

What is inside Trelegy Ellipta?

Trelegy Ellipta contains three active substances called fluticasone furoate, umeclidinium and vilanterol. Fluticasone furoate belongs to a group of medicines called corticosteroids, often simply called steroids. Umeclidinium and vilanterol belong to a group of medicines called bronchodilators[1]

How does Trelegy Ellipta work?

Trelegy Ellipta is used to treat chronic obstructive pulmonary disease (COPD) in adults. COPD is a long-term condition characterised by breathing difficulties that slowly get worse.

In COPD the muscles around the airways tighten, making breathing difficult.  This medicine widens these muscles in the lungs, reducing the swelling and irritation in the small air passages and making it easier for air to get in and out of the lungs.  When used regularly, it can help to control your breathing difficulties and reduce the effects of COPD on your everyday life. [1]

How do I take Trelegy Ellipta?

Always use this medicine exactly as your doctor has told you to. Check with your doctor, nurse or pharmacist if you are not sure.

The recommended dose is one inhalation every day at the same time of day. You only need to inhale once a day because the effect of this medicine lasts for 24 hours. [1]

Find out how to use your Ellipta inhaler.

Do I still need to use my reliever inhaler?

Yes. Trelegy Ellipta should not be used to relieve a sudden attack of breathlessness or wheezing. If you get this sort of attack you must use a quick-acting reliever inhaler (such as salbutamol).

If your COPD symptoms (breathlessness, wheezing, cough) do not improve or get worse, or if you are using your quick-acting reliever inhaler more often than usual contact your doctor as soon as possible.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this medicine.

Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline group of companies